Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

Change in Estimated Glomerular Filtration Rate (eGFR)

Time frame: Baseline to Week 24

Change in total cholesterol

Time frame: Baseline to Week 24

Change in Low-Density Lipoprotein-Cholesterol (LDL-C)

Time frame: Baseline to Week 24

Change in High-Density Lipoprotein-Cholesterol (HDL-C)

Time frame: Baseline to Week 24

Change in non-High-Density Lipoprotein-Cholesterol (non-HDL-C)

Time frame: Baseline to Week 24

Change in triglycerides

Time frame: Baseline to Week 24

Change in Apolipoprotein B (ApoB)

Time frame: Baseline to Week 24

Concentration of combined ALN-ANG3 and metabolite(s) and evinacumab

Time frame: Up to Week 24

Change in concentration of Angiopoietin-Like Protein-3 (ANGPTL-3)

Time frame: Baseline to Week 24

Occurrence of Treatment-Emergent Adverse Events (TEAEs)

Time frame: Up to Week 48

Severity of TEAEs

Time frame: Up to Week 48

Incidence of ADAs to ALN-ANG3

Time frame: Through Week 24

Magnitude of ADAs to ALN-ANG3

Time frame: Through Week 24

Incidence of ADAs to evinacumab

Time frame: Through Week 24

Magnitude of ADAs to evinacumab

Time frame: Through Week 24